AllianceBernstein’s CytomX Therapeutics CTMX Stock Holding History

AllianceBernstein’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$490K	Buy	+104,310	New	+$398K	﹤0.01%	2723
2022 Q2	–	Sell	-49,700	Closed	-$133K	–	3286
2022 Q1	$133K	Buy	49,700 +200	+0.4%	+$768	﹤0.01%	3078
2021 Q4	$214K	Sell	49,500 -900	-2%	-$5.27K	﹤0.01%	3048
2021 Q3	$257K	Sell	50,400 -6,700	-12%	-$35.9K	﹤0.01%	3005
2021 Q2	$361K	Buy	57,100 +10,300	+22%	+$80.2K	﹤0.01%	2955
2021 Q1	$362K	Sell	46,800 -16,100	-26%	-$127K	﹤0.01%	2824
2020 Q4	$412K	Hold	62,900	–	–	﹤0.01%	2676
2020 Q3	$418K	Sell	62,900 -1,500	-2%	-$11.1K	﹤0.01%	2618
2020 Q2	$536K	Hold	64,400	–	–	﹤0.01%	2569
2020 Q1	$494K	Buy	64,400 +5,600	+10%	+$39K	﹤0.01%	2360
2019 Q4	$489K	Sell	58,800 -87,837	-60%	-$593K	﹤0.01%	2556
2019 Q3	$1.08M	Sell	146,637 -21,350	-13%	-$211K	﹤0.01%	2216
2019 Q2	$1.89M	Hold	167,987	–	–	﹤0.01%	2008
2019 Q1	$1.81M	Buy	167,987 +69,917	+71%	+$1.03M	﹤0.01%	1951
2018 Q4	$1.48M	Hold	98,070	–	–	﹤0.01%	2001
2018 Q3	$1.81M	Hold	98,070	–	–	﹤0.01%	2016
2018 Q2	$2.24M	Buy	98,070 +23,800	+32%	+$608K	﹤0.01%	1830
2018 Q1	$2.11M	Sell	74,270 -7,720	-9%	-$220K	﹤0.01%	1780
2017 Q4	$1.73M	Buy	81,990 +8,300	+11%	+$172K	﹤0.01%	1950
2017 Q3	$1.34M	Hold	73,690	–	–	﹤0.01%	2118
2017 Q2	$1.14M	Buy	73,690 +39,090	+113%	+$589K	﹤0.01%	2228
2017 Q1	$598K	Buy	+34,600	New	+$455K	﹤0.01%	2477

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

AllianceBernstein's CTMX Position: Q2 2026 in Review

AllianceBernstein opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 104,310 shares worth $490K. The stake represents ﹤0.01% of the portfolio and ranks #2723 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in CTMX as recently as Q1 2022.

AllianceBernstein first reported a position in CTMX in Q1 2017 and has held it in 22 quarters since. The position peaked at $2.24M in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

AllianceBernstein held 104,310 shares of CytomX Therapeutics worth $490K as of Q2 2026.
CytomX Therapeutics was a new AllianceBernstein position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2723 holding.
AllianceBernstein first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 22 quarters since.
AllianceBernstein's CytomX Therapeutics position peaked at $2.24M in Q2 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.